特朗普：进口药品先征小额关税，最终税率将升至250%

Core Viewpoint - The article discusses President Trump's plans to impose tariffs on imported pharmaceuticals, potentially reaching up to 250%, aiming to encourage domestic production and address drug pricing issues in the U.S. [1][2][3] Group 1: Tariff Plans - Trump announced that the U.S. will initially impose "small tariffs" on imported drugs, with plans to increase the rate to 150% within a year and potentially to 250% thereafter [3] - The proposed tariffs are the highest Trump has threatened to impose on pharmaceuticals, with previous threats including a 200% tariff [2][3] - The administration initiated a "232 clause investigation" to assess whether imports pose a national security threat [4] Group 2: Industry Impact - The tariffs are intended to incentivize pharmaceutical companies to relocate production back to the U.S., as domestic production has significantly declined over the past decades [5] - In response to the tariff threats, companies like Eli Lilly and Johnson & Johnson have announced plans to increase investments in the U.S. [6] - However, the proposed tariffs could negatively impact the pharmaceutical industry by raising costs, suppressing U.S. investments, and disrupting drug supply chains, potentially putting patients at risk [8] Group 3: Drug Pricing Policies - Pharmaceutical companies are already facing challenges from Trump's drug pricing policies, which threaten profits and research investment capabilities [9] - Trump signed an executive order in May to revive the "Most Favored Nation" policy, linking U.S. drug prices to significantly lower prices abroad [9] - Trump has also reached out to 17 global pharmaceutical companies, demanding commitments to lower U.S. drug prices by September 29 [10]